000128162 001__ 128162
000128162 005__ 20240228135044.0
000128162 0247_ $$2doi$$a10.1007/s00330-013-3017-5
000128162 0247_ $$2pmid$$apmid:24196383
000128162 0247_ $$2ISSN$$a0938-7994
000128162 0247_ $$2ISSN$$a1432-1084
000128162 0247_ $$2ISSN$$a1613-3749
000128162 0247_ $$2ISSN$$a1613-3757
000128162 037__ $$aDKFZ-2017-04180
000128162 041__ $$aeng
000128162 082__ $$a610
000128162 1001_ $$0P:(DE-He78)3d11afed6b72f876ad1bba9418e30dac$$aRöthke, Matthias$$b0$$eFirst author$$udkfz
000128162 245__ $$aEvaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla.
000128162 260__ $$aBerlin$$bSpringer$$c2014
000128162 3367_ $$2DRIVER$$aarticle
000128162 3367_ $$2DataCite$$aOutput Types/Journal article
000128162 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521814776_5360
000128162 3367_ $$2BibTeX$$aARTICLE
000128162 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128162 3367_ $$00$$2EndNote$$aJournal Article
000128162 520__ $$aTo evaluate the Prostate Imaging Reporting and Data System (PI-RADS) proposed by the European Society of Urogenital Radiology (ESUR) for detection of prostate cancer (PCa) by multiparametric magnetic resonance imaging (mpMRI) in a consecutive cohort of patients with magnetic resonance/transrectal ultrasound (MR/TRUS) fusion-guided biopsy.Suspicious lesions on mpMRI at 3.0 T were scored according to the PI-RADS system before MR/TRUS fusion-guided biopsy and correlated to histopathology results. Statistical correlation was obtained by a Mann-Whitney U test. Receiver operating characteristics (ROC) and optimal thresholds were calculated.In 64 patients, 128/445 positive biopsy cores were obtained out of 95 suspicious regions of interest (ROIs). PCa was present in 27/64 (42%) of the patients. ROC results for the aggregated PI-RADS scores exhibited higher areas under the curve compared to those of the Likert score. Sensitivity/Specificity for the following thresholds were calculated: 85 %/73 % and 67 %/92 % for PI-RADS scores of 9 and 10, respectively; 85 %/60 % and 56 %/97 % for Likert scores of 3 and 4, respectively [corrected.The standardised ESUR PI-RADS system is beneficial to indicate the likelihood of PCa of suspicious lesions on mpMRI. It is also valuable to identify locations to be targeted with biopsy. The aggregated PI-RADS score achieved better results compared to the single five-point Likert score.• The ESUR PI-RADS scoring system was evaluated using multiparametric 3.0-T MRI. • To investigate suspicious findings, transperineal MR/TRUS fusion-guided biopsy was used. • PI-RADS can guide biopsy locations and improve detection of clinically significant cancer. • Biopsy procedures can be optimised, reducing unnecessary negative biopsies for patients. • The PI-RADS scoring system may contribute to more effective prostate MRI.
000128162 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000128162 588__ $$aDataset connected to CrossRef, PubMed,
000128162 7001_ $$0P:(DE-HGF)0$$aKuru, T. H.$$b1
000128162 7001_ $$aSchultze, S.$$b2
000128162 7001_ $$0P:(DE-He78)2ef631585610340ff425c9c31fcabd03$$aTichy, D.$$b3$$udkfz
000128162 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, A.$$b4$$udkfz
000128162 7001_ $$aFenchel, M.$$b5
000128162 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b6$$udkfz
000128162 7001_ $$aHadaschik, B. A.$$b7
000128162 773__ $$0PERI:(DE-600)1472718-3$$a10.1007/s00330-013-3017-5$$gVol. 24, no. 2, p. 344 - 352$$n2$$p344 - 352$$tEuropean radiology$$v24$$x1432-1084$$y2014
000128162 909CO $$ooai:inrepo02.dkfz.de:128162$$pVDB
000128162 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d11afed6b72f876ad1bba9418e30dac$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000128162 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000128162 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2ef631585610340ff425c9c31fcabd03$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000128162 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000128162 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000128162 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000128162 9141_ $$y2014
000128162 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000128162 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR RADIOL : 2015
000128162 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128162 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128162 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128162 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000128162 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000128162 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128162 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128162 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128162 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128162 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000128162 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000128162 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x0
000128162 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000128162 980__ $$ajournal
000128162 980__ $$aVDB
000128162 980__ $$aI:(DE-He78)E010-20160331
000128162 980__ $$aI:(DE-He78)C060-20160331
000128162 980__ $$aUNRESTRICTED